Use of liposomized tetracycline in elimination of Wolbachia endobacterium of human lymphatic filariid Brugia malayi in a rodent model.
Identifieur interne : 003B65 ( PubMed/Corpus ); précédent : 003B64; suivant : 003B66Use of liposomized tetracycline in elimination of Wolbachia endobacterium of human lymphatic filariid Brugia malayi in a rodent model.
Auteurs : Preeti Bajpai ; Satish Vedi ; Mohammad Owais ; Sharad K. Sharma ; Prabh N. Saxena ; Shailja Misra-BhattacharyaSource :
- Journal of drug targeting [ 1061-186X ] ; 2005.
English descriptors
- KwdEn :
- Administration, Oral, Animals, Anti-Bacterial Agents (administration & dosage), Anti-Bacterial Agents (therapeutic use), Brugia malayi (drug effects), Disease Models, Animal, Elephantiasis, Filarial (drug therapy), Female, Humans, Liposomes, Rats, Tetracycline (administration & dosage), Tetracycline (therapeutic use), Wolbachia (drug effects), Wolbachia (pathogenicity).
- MESH :
- chemical , administration & dosage : Anti-Bacterial Agents, Tetracycline.
- chemical , therapeutic use : Anti-Bacterial Agents, Tetracycline.
- drug effects : Brugia malayi, Wolbachia.
- drug therapy : Elephantiasis, Filarial.
- pathogenicity : Wolbachia.
- Administration, Oral, Animals, Disease Models, Animal, Female, Humans, Liposomes, Rats.
Abstract
Wolbachia bacteria, being filarial parasite symbiont have been implicated in a variety of roles, including development, fecundity and the pathogenesis of the filarial infections. Among various strategies used in the treatment of experimental filariasis, the elimination of symbiont Wolbachia seem to offer an efficient means of curing the disease. The antiwolbachial property of tetracycline has been well worked out; however, treatment needs to be continued for a prolonged period of time to achieve complete elimination of Wolbachia from the filarial parasites and their subsequent killing. This results in acute toxicity, thus limiting its practical utility for clinical implementation. In order to increase efficacy of the antibiotic with minimal toxic manifestations, we developed liposomized formulation of the tetracycline. The liposomized tetracycline was found to be significantly more effective when compared to the free form of the drug. In contrast to the 90/120 days oral administration of the drug, the treatment schedule using the liposomized form of the drug was reduced to 12 alternate days with better efficacy of the treatment.
DOI: 10.1080/10611860500285439
PubMed: 16278157
Links to Exploration step
pubmed:16278157Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Use of liposomized tetracycline in elimination of Wolbachia endobacterium of human lymphatic filariid Brugia malayi in a rodent model.</title>
<author><name sortKey="Bajpai, Preeti" sort="Bajpai, Preeti" uniqKey="Bajpai P" first="Preeti" last="Bajpai">Preeti Bajpai</name>
<affiliation><nlm:affiliation>Central Drug Research Institute, Divisions of Parasitology, Lucknow, India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Vedi, Satish" sort="Vedi, Satish" uniqKey="Vedi S" first="Satish" last="Vedi">Satish Vedi</name>
</author>
<author><name sortKey="Owais, Mohammad" sort="Owais, Mohammad" uniqKey="Owais M" first="Mohammad" last="Owais">Mohammad Owais</name>
</author>
<author><name sortKey="Sharma, Sharad K" sort="Sharma, Sharad K" uniqKey="Sharma S" first="Sharad K" last="Sharma">Sharad K. Sharma</name>
</author>
<author><name sortKey="Saxena, Prabh N" sort="Saxena, Prabh N" uniqKey="Saxena P" first="Prabh N" last="Saxena">Prabh N. Saxena</name>
</author>
<author><name sortKey="Misra Bhattacharya, Shailja" sort="Misra Bhattacharya, Shailja" uniqKey="Misra Bhattacharya S" first="Shailja" last="Misra-Bhattacharya">Shailja Misra-Bhattacharya</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2005">2005</date>
<idno type="RBID">pubmed:16278157</idno>
<idno type="pmid">16278157</idno>
<idno type="doi">10.1080/10611860500285439</idno>
<idno type="wicri:Area/PubMed/Corpus">003B65</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003B65</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Use of liposomized tetracycline in elimination of Wolbachia endobacterium of human lymphatic filariid Brugia malayi in a rodent model.</title>
<author><name sortKey="Bajpai, Preeti" sort="Bajpai, Preeti" uniqKey="Bajpai P" first="Preeti" last="Bajpai">Preeti Bajpai</name>
<affiliation><nlm:affiliation>Central Drug Research Institute, Divisions of Parasitology, Lucknow, India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Vedi, Satish" sort="Vedi, Satish" uniqKey="Vedi S" first="Satish" last="Vedi">Satish Vedi</name>
</author>
<author><name sortKey="Owais, Mohammad" sort="Owais, Mohammad" uniqKey="Owais M" first="Mohammad" last="Owais">Mohammad Owais</name>
</author>
<author><name sortKey="Sharma, Sharad K" sort="Sharma, Sharad K" uniqKey="Sharma S" first="Sharad K" last="Sharma">Sharad K. Sharma</name>
</author>
<author><name sortKey="Saxena, Prabh N" sort="Saxena, Prabh N" uniqKey="Saxena P" first="Prabh N" last="Saxena">Prabh N. Saxena</name>
</author>
<author><name sortKey="Misra Bhattacharya, Shailja" sort="Misra Bhattacharya, Shailja" uniqKey="Misra Bhattacharya S" first="Shailja" last="Misra-Bhattacharya">Shailja Misra-Bhattacharya</name>
</author>
</analytic>
<series><title level="j">Journal of drug targeting</title>
<idno type="ISSN">1061-186X</idno>
<imprint><date when="2005" type="published">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Oral</term>
<term>Animals</term>
<term>Anti-Bacterial Agents (administration & dosage)</term>
<term>Anti-Bacterial Agents (therapeutic use)</term>
<term>Brugia malayi (drug effects)</term>
<term>Disease Models, Animal</term>
<term>Elephantiasis, Filarial (drug therapy)</term>
<term>Female</term>
<term>Humans</term>
<term>Liposomes</term>
<term>Rats</term>
<term>Tetracycline (administration & dosage)</term>
<term>Tetracycline (therapeutic use)</term>
<term>Wolbachia (drug effects)</term>
<term>Wolbachia (pathogenicity)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-Bacterial Agents</term>
<term>Tetracycline</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Bacterial Agents</term>
<term>Tetracycline</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Brugia malayi</term>
<term>Wolbachia</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Wolbachia</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term>
<term>Animals</term>
<term>Disease Models, Animal</term>
<term>Female</term>
<term>Humans</term>
<term>Liposomes</term>
<term>Rats</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Wolbachia bacteria, being filarial parasite symbiont have been implicated in a variety of roles, including development, fecundity and the pathogenesis of the filarial infections. Among various strategies used in the treatment of experimental filariasis, the elimination of symbiont Wolbachia seem to offer an efficient means of curing the disease. The antiwolbachial property of tetracycline has been well worked out; however, treatment needs to be continued for a prolonged period of time to achieve complete elimination of Wolbachia from the filarial parasites and their subsequent killing. This results in acute toxicity, thus limiting its practical utility for clinical implementation. In order to increase efficacy of the antibiotic with minimal toxic manifestations, we developed liposomized formulation of the tetracycline. The liposomized tetracycline was found to be significantly more effective when compared to the free form of the drug. In contrast to the 90/120 days oral administration of the drug, the treatment schedule using the liposomized form of the drug was reduced to 12 alternate days with better efficacy of the treatment.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16278157</PMID>
<DateCreated><Year>2005</Year>
<Month>11</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted><Year>2005</Year>
<Month>12</Month>
<Day>15</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">1061-186X</ISSN>
<JournalIssue CitedMedium="Print"><Volume>13</Volume>
<Issue>6</Issue>
<PubDate><Year>2005</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Journal of drug targeting</Title>
<ISOAbbreviation>J Drug Target</ISOAbbreviation>
</Journal>
<ArticleTitle>Use of liposomized tetracycline in elimination of Wolbachia endobacterium of human lymphatic filariid Brugia malayi in a rodent model.</ArticleTitle>
<Pagination><MedlinePgn>375-81</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Wolbachia bacteria, being filarial parasite symbiont have been implicated in a variety of roles, including development, fecundity and the pathogenesis of the filarial infections. Among various strategies used in the treatment of experimental filariasis, the elimination of symbiont Wolbachia seem to offer an efficient means of curing the disease. The antiwolbachial property of tetracycline has been well worked out; however, treatment needs to be continued for a prolonged period of time to achieve complete elimination of Wolbachia from the filarial parasites and their subsequent killing. This results in acute toxicity, thus limiting its practical utility for clinical implementation. In order to increase efficacy of the antibiotic with minimal toxic manifestations, we developed liposomized formulation of the tetracycline. The liposomized tetracycline was found to be significantly more effective when compared to the free form of the drug. In contrast to the 90/120 days oral administration of the drug, the treatment schedule using the liposomized form of the drug was reduced to 12 alternate days with better efficacy of the treatment.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bajpai</LastName>
<ForeName>Preeti</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Central Drug Research Institute, Divisions of Parasitology, Lucknow, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Vedi</LastName>
<ForeName>Satish</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Owais</LastName>
<ForeName>Mohammad</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Sharma</LastName>
<ForeName>Sharad K</ForeName>
<Initials>SK</Initials>
</Author>
<Author ValidYN="Y"><LastName>Saxena</LastName>
<ForeName>Prabh N</ForeName>
<Initials>PN</Initials>
</Author>
<Author ValidYN="Y"><LastName>Misra-Bhattacharya</LastName>
<ForeName>Shailja</ForeName>
<Initials>S</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>J Drug Target</MedlineTA>
<NlmUniqueID>9312476</NlmUniqueID>
<ISSNLinking>1026-7158</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008081">Liposomes</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>F8VB5M810T</RegistryNumber>
<NameOfSubstance UI="D013752">Tetracycline</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017178" MajorTopicYN="N">Brugia malayi</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008081" MajorTopicYN="N">Liposomes</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013752" MajorTopicYN="N">Tetracycline</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020577" MajorTopicYN="N">Wolbachia</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year>
<Month>11</Month>
<Day>10</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2005</Year>
<Month>12</Month>
<Day>16</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2005</Year>
<Month>11</Month>
<Day>10</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">16278157</ArticleId>
<ArticleId IdType="pii">X547H50V25L71257</ArticleId>
<ArticleId IdType="doi">10.1080/10611860500285439</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003B65 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 003B65 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:16278157 |texte= Use of liposomized tetracycline in elimination of Wolbachia endobacterium of human lymphatic filariid Brugia malayi in a rodent model. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:16278157" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
![]() | This area was generated with Dilib version V0.6.31. | ![]() |